%0 Journal Article
%T 免疫检查点抑制剂在子宫内膜癌中的治疗与新进展<br>Treatment of Immune Checkpoint Inhibitors in Endometrial Cancer and New Advances
%A 王艳婷
%A 魏梦凡
%A 赵红
%J Advances in Clinical Medicine
%P 12369-12377
%@ 2161-8720
%D 2023
%I Hans Publishing
%R 10.12677/ACM.2023.1381734
%X 近年来，随着医学领域在人体免疫方面进行越来越多的研究，免疫疗法在实体肿瘤中的治疗取得了良好的疗效。由于子宫内膜癌(Endometrialcancer, EC)中存在不同的分子亚型和免疫失调，免疫检查点阻断已被探索作为一种新的治疗机制。本文总结了现有的临床数据，以及正在进行和计划中的临床试验，就免疫检查点抑制剂(immune checkpoint inhibitor, ICI)在子宫内膜癌中的应用现状及联合治疗、局限性进行了综述，并展望了未来最有希望的研究方向。<br />
In recent years, as the medical field has conducted more and more research in human immunity, immunotherapy has achieved good efficacy in the treatment of solid tumors. Due to the presence of different molecular subtypes and immune dysregulation in endometrial cancer (EC), immune checkpoint blockade has been explored as a new therapeutic mechanism. In this article, we sum-marize the available clinical data, as well as ongoing and planned clinical trials, and review the cur-rent status of immune checkpoint inhibitor (ICI) use in endometrial cancer and its combination therapy, limitations, and look at the most promising future research directions.
%K 免疫疗法，免疫检查点抑制剂，子宫内膜癌，PD-1/PD-L1，CTLA-4，联合治疗<br>Immunotherapy
%K Immune Checkpoint Inhibitors
%K Endometrial Cancer
%K PD-1/PD-L1
%K CTLA-4
%K Combination Therapy
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=70335